Q2 2026 highlights

GSK delivers strong Q2 core results performance and continued momentum; Plans announced to accelerate R&D and late-stage pipeline portfolio

Total sales

£8.4bn +5%

Specialty Medicines

£3.8bn +14%

Respiratory, Immunology and Inflammation +19%

Oncology +17%

HIV +10%

Vaccines

£2.3bn +8%

General Medicines

£2.3bn -9%

Core operating profit

£2.8bn +7%

Core EPS

50.5p +9%

Total EPS

10.8p -69%

Dividend

17p

62 assets in clinical development with opportunities for significant growth

7 asset accelerations – across 18 indications – identified in: Oncology, Respiratory, Hepatology and Vaccines

Now expect 20+ phase III trial starts in 2026 (previously 10)

New flagship R&D Centre to be established in Cambridge Biomedical Campus, UK

3-year programme to fund investment in late-stage portfolio and to improve operating margin

"GSK has delivered another quarter of strong core results performance, with our key growth drivers performing well. We remain focused on operational delivery, execution, and accelerating R&D.

To that end, we have identified late-stage pipeline accelerations – across 18 indications – for 7 key assets in Oncology, Respiratory, Hepatology and Vaccines. Based on clinical data, and their opportunities to improve upon current standards-of-care, we see strong reasons for all these assets to bring meaningful benefits and protection to patients.

We have also decided to establish a new flagship R&D Centre on the UK's Cambridge Biomedical Campus – an investment that will further integrate GSK into one of the world's leading ecosystems for life-sciences.

To fund investment in the late-stage portfolio and R&D, we are starting a 3-year cost savings programme to simplify the organisation and to reallocate capital and resources. Savings will primarily be reinvested, with some used to improve margins and profitability in the dolutegravir patent expiry period (2028-2030).

We believe these plans, together with continued disciplined capital allocation, will drive strong operational performance and shareholder returns over the next five years, delivering our 2031 sales outlook and accelerated long-term growth."

Luke Miels,
Chief Executive Officer, GSK

Journalists/media see press release on www.gsk.com for full details on Q2 2026.
Please read the 'Guidance and outlooks, assumptions and cautionary statements' on pages 52-53 of the Q2 press release.
Certain non-IFRS measures are defined on pages 50-51 of the Q2 press release.
Product group sales may not add to total sales due to rounding.
References to growth are at constant exchange rates (CER) unless stated otherwise.